1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kyowa Kirin Co. Ltd.
  6. Summary
    4151   JP3256000005

KYOWA KIRIN CO. LTD.

(4151)
  Report
Delayed Japan Exchange  -  10:30 2022-07-03 pm EDT
3060.00 JPY   +0.82%
06/30Ardelyx Enters Financing Agreement of Up to $20 Million With HealthCare Royalty Partners; Shares Rise Pre-Bell
MT
06/30Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive Adc Data
CI
06/29KYOWA KIRIN CO. LTD. : Ex-dividend day for interim dividend
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/03/2022 Date
3105(c) 3055(c) 3050(c) 3035(c) 3060 Last
759 100 1 708 900 1 199 000 757 200 224 400 Volume
+0.81% -1.61% -0.16% -0.49% +0.82% Change
More quotes
Estimated financial data (e)
Sales 2022 387 B 2 862 M 2 862 M
Net income 2022 56 627 M 419 M 419 M
Net cash position 2022 348 B 2 573 M 2 573 M
P/E ratio 2022 28,8x
Yield 2022 1,58%
Sales 2023 415 B 3 069 M 3 069 M
Net income 2023 66 237 M 490 M 490 M
Net cash position 2023 372 B 2 751 M 2 751 M
P/E ratio 2023 24,6x
Yield 2023 1,74%
Capitalization 1 631 B 12 062 M 12 062 M
EV / Sales 2022 3,32x
EV / Sales 2023 3,03x
Nbr of Employees 5 752
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin Co., Ltd.) specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (94.1%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (5.9%). At the end of 2019, the group had 3... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Kyowa Kirin Co. Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about KYOWA KIRIN CO. LTD.
06/30Ardelyx Enters Financing Agreement of Up to $20 Million With HealthCare Royalty Partner..
MT
06/30Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights B..
CI
06/29KYOWA KIRIN CO. LTD. : Ex-dividend day for interim dividend
FA
06/24Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for the Treatment of Tum..
CI
06/10Nikkei 225 Down 1.5% on ECB Rate Hike, US CPI Outlook
MT
06/09Kyowa Kirin CEO Miyamoto's Message on Pride Month
AQ
06/04MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society o..
CI
06/02Kyowa Kirin Presents Positive Data from Phase 3 Study of LUMICEF in Systemic Sclerosis ..
AQ
06/01InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration
AQ
05/31InveniAI and Kyowa Kirin Co., Ltd. Announce Achievement of Milestone in Research Collab..
CI
05/18Kyowa Kirin to Start Construction of a New Biopharmaceutical API Manufacturing Building..
AQ
05/18Luca Science and Kyowa Kirin Announces Joint Research Agreement on Mitochondrial Diseas..
CI
05/11Kyowa Kirin's Attributable Profit Rises 24% in Q1
MT
05/10Nitto Denko Corporation Provides Consolidated Earnings Guidance for the Fiscal Year End..
CI
05/10Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year E..
CI
More news
News in other languages on KYOWA KIRIN CO. LTD.
06/30Ardelyx conclut un accord de financement d'un montant maximal de 20 millions de dollars..
06/30Kyowa Kirin étend l'accord de licence avec Synaffix et prend les droits exclusifs sur l..
06/24Kyowa Kirin reçoit un avis positif du CHMP pour l'utilisation de CRYSVITA (burosumab) d..
06/17Tokyo finit à son plus bas niveau depuis plus d'un mois
06/16Tokyo en forte baisse derrière Wall Street
More news
Chart KYOWA KIRIN CO. LTD.
Duration : Period :
Kyowa Kirin Co. Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KYOWA KIRIN CO. LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 035,00 JPY
Average target price 3 597,50 JPY
Spread / Average Target 18,5%
EPS Revisions
Managers and Directors
Masashi Miyamoto President, CEO & Representative Director
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Nobuo Hanai Chairman
Mitsuo Satoh Executive Officer, GM-Research & Development
Kentaro Uryu Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
KYOWA KIRIN CO. LTD.-3.19%12 062
MERCK KGAA-27.00%74 935
SK BIOPHARMACEUTICALS CO., LTD.-27.57%4 240
BETTA PHARMACEUTICALS CO., LTD.-30.24%3 452
YUHAN CORPORATION-9.82%2 930
INDIVIOR PLC18.52%2 559